Can CYP2C19 genotyping improve antiplatelet therapy efficacy in real-life practice? Recent advances.

Abstract excerpt

Clopidogrel remains the most widely used P2Y12 receptor inhibitor worldwide and is often used in combination with aspirin for secondary prevention in patients with arterial disease. The drug is associated with a wide variation in responses, with one in 3 patients exhibiting little or no inhibition of adenosine diphosphate-induced platelet aggregation. It is a prodrug that is mainly metabolized by hepatic...

Topics

Join the communities discussing this publication.

• Clopidogrel
• Cytochrome P-450 CYP2C19
• CYP2C19 gene
• Genotype
• Platelet Aggregation Inhibitors